Enhances sexual desire
Activates brain pathways responsible for arousal and desire, not just physical function.
PT-141 is administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity. It is used on an as-needed basis rather than daily. Nasal spray formulations are also available. Your provider will determine the appropriate dose based on your individual response and health profile.
All dosing is determined by your licensed provider based on your health profile.
Do not self-administer without medical supervision.
PT-141
Enhances sexual arousal and desire through central nervous system activation.
Starting at
$179/month
All plans include doctor review, personalized treatment plan, and 24/7 provider access.
Unlimited 24/7 support
No hidden fees
No insurance required
Same price, every dose
PT-141 is administered as a subcutaneous injection approximately 45 minutes before anticipated sexual activity. It is used on an as-needed basis rather than daily. Nasal spray formulations are also available. Your provider will determine the appropriate dose based on your individual response and health profile.
All dosing is determined by your licensed provider based on your health profile. Do not self-administer without medical supervision.
- Generic name
- Bremelanotide
- Onset
- ~45 minutes
- Form
- Injectable / Nasal spray
- Availability
- Prescription only
Viagra (sildenafil) works by increasing blood flow to the genitals. PT-141 works in the brain by activating melanocortin receptors that control sexual desire and arousal. This means PT-141 addresses desire itself, not just physical function.
PT-141 (marketed as Vyleesi/Bremelanotide) received FDA approval in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is also used off-label in men under physician guidance.
PT-141 typically takes effect within 45 minutes of subcutaneous injection. Effects can last for several hours, though individual response times may vary.
How PT-141 works
PT-141 activates melanocortin-4 receptors (MC4R) in the central nervous system, specifically in brain regions associated with sexual arousal and desire. Unlike PDE5 inhibitors (such as sildenafil) that work by increasing blood flow, PT-141 works at the neurological level to enhance sexual responsiveness. This central mechanism makes it effective for both men and women, addressing desire and arousal rather than just the physical mechanics of sexual function.
Clinical evidence
PT-141 (Bremelanotide) received FDA approval in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Phase III trials demonstrated statistically significant improvements in sexual desire and reductions in distress related to low sexual desire. Earlier studies in men with erectile dysfunction showed efficacy even in patients who did not respond to PDE5 inhibitors. The compound has been evaluated in multiple large-scale randomized controlled trials.
Benefits
Works for men and women
Central mechanism of action is effective regardless of gender.
Independent of vascular function
Works through the CNS rather than blood vessels, effective even when PDE5 inhibitors fail.
Fast-acting and on-demand
Can be administered as-needed before sexual activity with rapid onset.
Enhances sexual desire
Activates brain pathways responsible for arousal and desire, not just physical function.
Works for men and women
Central mechanism of action is effective regardless of gender.
Independent of vascular function
Works through the CNS rather than blood vessels, effective even when PDE5 inhibitors fail.
Fast-acting and on-demand
Can be administered as-needed before sexual activity with rapid onset.
Key takeaways
- FDA-approved (as Vyleesi) for HSDD in premenopausal women
- Works through central nervous system melanocortin receptor activation
- Effective for both men and women
- On-demand dosing approximately 45 minutes before activity
- Effective even when PDE5 inhibitors fail
Bundle savings
Savings apply when multiple peptides are prescribed.
| BUNDLE SIZE | INCLUDED | SAVINGS |
|---|---|---|
| 2 Peptides | Simple paired therapy | SAVE 20• |
| 3 Peptides | Multi-pathway plan | SAVE 30• |
| 4 Peptides | Full personalized set | BEST VALUE |
• Results vary. Prescribed only when clinically appropriate.
Peptide Library
Each plan may include several of the following formulations.
The science behind it
Proven science
Every peptide we offer is backed by peer-reviewed research and clinical data. Our medical team stays current with the latest findings to ensure your protocol reflects the best available science.
Discreet delivery
Your medications arrive in unmarked, temperature-controlled packaging shipped directly from licensed compounding pharmacies. Privacy and quality guaranteed at every step.
Doctor-supervised safety
Every treatment is prescribed and monitored by a licensed physician. Regular check-ins, lab reviews, and dosage adjustments ensure your peptide therapy is safe and effective throughout your journey.
Clinician-Led Care
Eligibility check
Quick online assessment
Consultation
Licensed provider reviews your medical history
Prescription
Medication shipped directly once approved
Follow-ups
Ongoing support and check-ins
Eligibility check
Quick online assessment
Consultation
Licensed provider reviews your medical history
Prescription
Medication shipped directly once approved
Follow-ups
Ongoing support and check-ins
Secure telehealth · GDPR-compliant · Pharmacy-grade compounding.
Check eligibility →
Not for self-administration. Reviewed by a medical provider.
Medication made affordable
Capsules
$179/mo
Single Peptide
$229/mo
Double Combo
$349/mo
Triple Combo
$479/mo
Capsules
$179/mo
Single Peptide
$229/mo
Double Combo
$349/mo
Triple Combo
$479/mo
All plans include a doctor review, personalized treatment plan (if approved), and 24/7 access to a licensed provider in your state.
Related treatments
Frequently asked questions
Viagra (sildenafil) works by increasing blood flow to the genitals. PT-141 works in the brain by activating melanocortin receptors that control sexual desire and arousal. This means PT-141 addresses desire itself, not just physical function.
PT-141 (marketed as Vyleesi/Bremelanotide) received FDA approval in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. It is also used off-label in men under physician guidance.
PT-141 typically takes effect within 45 minutes of subcutaneous injection. Effects can last for several hours, though individual response times may vary.
The most commonly reported side effects include temporary nausea, flushing, and headache. Some individuals may experience mild increases in blood pressure. Side effects are generally mild and transient.
PT-141 is designed for on-demand use rather than daily administration. Most protocols recommend no more than 1 dose per 24 hours and no more than 8 doses per month. Your provider will guide appropriate frequency.
Begin your health journey today
Doctor-guided peptide treatments personalized to your health goals. Start with a free consultation
Starting at
$179/month
All plans include doctor review, personalized treatment plan, and 24/7 provider access.